secwatch.observer — SEC 8-K summary
======================================

Issuer:     PUMA BIOTECHNOLOGY, INC. (PBYI)
CIK:        0001401667
Form:       8-K
Filed at:   2025-08-07T23:59:59+00:00
Accession:  0001437749-25-025463
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Puma Biotechnology Q2 net income $5.9M vs year-ago loss; revenue rises to $52.4M
--------------------------------------------------------------------------------

- GAAP EPS $0.12 vs $(0.09) loss; adjusted EPS $0.15 vs $(0.05) loss.
- Net product revenue $49.2M (+11% YoY); total revenue $52.4M (+11% YoY).
- Q3 2025 guidance: net product revenue $46–48M, total revenue $48–51M, net income $2–4M.
- Full-year 2025 revenue outlook reaffirmed at $212–222M; gross-to-net adjustment raised to 21.5–22.0%.
- Cash & equivalents $96M; key milestones: alisertib interim data in Q4 2025 for two Phase II trials.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1401667/000143774925025463/0001437749-25-025463-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1401667/000143774925025463/pbyi20250724_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-25-025463

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer